

# CATEGORY 1

## REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 9612090341      DOC. DATE: 96/12/02      NOTARIZED: NO      DOCKET #  
FACIL: 50-269 Oconee Nuclear Station, Unit 1, Duke Power Co.      05000269  
50-270 Oconee Nuclear Station, Unit 2, Duke Power Co.      05000270  
50-287 Oconee Nuclear Station, Unit 3, Duke Power Co.      05000287  
50-369 William B. McGuire Nuclear Station, Unit 1, Duke Powe      05000369  
50-370 William B. McGuire Nuclear Station, Unit 2, Duke Powe      05000370  
50-413 Catawba Nuclear Station, Unit 1, Duke Power Co.      05000413  
50-414 Catawba Nuclear Station, Unit 2, Duke Power Co.      05000414

AUTH. NAME      AUTHOR AFFILIATION  
TUCKMAN, M.S.      Duke Power Co.  
RECIP. NAME      RECIPIENT AFFILIATION  
                         Document Control Branch (Document Control Desk)

SUBJECT: Forwards unsatisfactory performance test results for FFD program for plants.

DISTRIBUTION CODE: A022D      COPIES RECEIVED: LTR 1 ENCL 1 SIZE: 5  
TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES:

	RECIPIENT ID CODE/NAME	COPIES LTR ENCL	RECIPIENT ID CODE/NAME	COPIES LTR ENCL
	PD2-2 PD	1 1	LABARGE, D	1 1
	NERSES, V	1 1	TAM, P.	1 1
INTERNAL:	ACRS	1 1	FILE CENTER 01	1 1
	NRR/DRPM/PERB	1 1	NRR/DRPM/PSGB	1 1
	NUDOCS-ABSTRACT	1 1	RGN2	1 1
EXTERNAL:	NOAC	1 1	NRC PDR	1 1

NOTE TO ALL "RIDS" RECIPIENTS:  
PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK,  
ROOM OWFN 5D-5 (EXT. 415-2083) TO ELIMINATE YOUR NAME FROM  
DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTR 12 ENCL 12

C  
A  
T  
E  
G  
O  
R  
Y  
1  
D  
O  
C  
U  
M  
E  
N  
T

Duke Power Company  
P.O. Box 1006  
Charlotte, NC 28201-1006

M. S. TUCKMAN  
Senior Vice President  
Nuclear Generation  
(704)382-2200 Office  
(704)382-4360 Fax



**DUKE POWER**

December 2, 1996

U. S. Nuclear Regulatory Commission  
Attn: Document Control Desk  
Washington, D. C. 20555

Subject: Fitness-For-Duty Program  
Unsatisfactory Performance Test Result

Oconee Nuclear Station  
Docket Numbers 50-269, -270 and -287  
McGuire Nuclear Station  
Docket Numbers 50-369 and -370  
Catawba Nuclear Station  
Docket Numbers 50-413 and -414

Attached is a report, as required by 10CFR 26, Appendix A,  
of unsatisfactory performance test results.

If there are any questions, please contact G. A. Copp at  
(704) 382-5826.

Very truly yours,

*M. S. Tuckman*

M. S. Tuckman

9612090341 961202  
PDR ADOCK 05000269  
R. PDR

A022 1/1

090062

U. S. Nuclear Regulatory Commission  
December 2, 1996  
Page 2

Mr. Victor Nerses, Project Manager  
Office of Nuclear Reactor Regulation  
U. S. Nuclear Regulatory Commission  
Mail Stop 14H25, OWFN  
Washington. D. C. 20555

Mr. Peter S. Tam, Project Manager  
Office of Nuclear Reactor Regulation  
U. S. Nuclear Regulatory Commission  
Mail Stop 14H25, OWFN  
Washington, D. C. 20555

Mr. D. E. Lebarge, Project Manager  
Office of Nuclear Reactor Regulation  
U. S. Nuclear Regulatory Commission  
Washington. D. C. 20555

Mr. S. D. Ebnetter, Regional Administrator  
U. S. Nuclear Regulatory Commission - Region II  
101 Marietta Street, NW - Suite 2900  
Atlanta, GA 30323

Duke Power Company  
Health & Safety Division  
P.O. Box 1006 (EC020)  
Charlotte, NC 28201-1006



**DUKE POWER**

November 25, 1996

SUBJECT: False Negative Blind Urine Drug Screen

A blind specimen spiked with amphetamine was identified as negative by the SmithKline Beecham Laboratory in Atlanta. The specimen was submitted from McGuire Nuclear Station in September, 1996.

Dr. Jerry McHan of Quality Assurance Associates notified me of the results on November 8, 1996. Dr. McHan has investigated the result with Dr. Feldman of the laboratory. A report from Dr. Feldman is attached.

The laboratory correctly identified 6 of 7 specimens spiked with amphetamine in the 3rd quarter of 1996. The one missed was just under the cutoff level.

*William E. Dukes, Jr., MD*

William E. Dukes, Jr., MD  
Corporate Medical Director

WED/sap  
Enclosure

**SB**  
**SmithKline Beecham**  
*Clinical Laboratories*

Dr. Gene Dukes  
Corporate Medical Director  
Duke Power Company  
422 S. Church St.  
Charlotte, NC 28242

Nov. 18, 1996,

Re: Blind QC Audit, 646615J

Dear Dr. Dukes:

The above specimen was reported as negative, based on an amphetamine screening result of 0.884 (1.000 is cutoff).


At the end of spring, the new J1 lot of Behring (Syva) amphetamine reagent replaced our old lot, and was verified for acceptable reactivity to d-methamphetamine and d-amphetamine on our AU5000 screening instruments. Over the summer, our Olympus AU5000 screening instruments were replaced with new AU800 instruments. Although the AU800s were properly validated for the amphetamines class with d-methamphetamine calibrator and control materials, the reactivity for d-amphetamine was not checked. Behring's own d-amphetamine studies were performed only on AU5000 instruments.

In response to your feedback, we have checked the four AU800s, and they give appropriate response for d-amphetamine, however there is variation between the instruments. We have looked at the AU800 screening results from other blind QC samples that were properly reported as positive, and at negative urine samples spiked with 1500 ng/ml d-amphetamine. All gave similar positive screening results, and similar GC/MS concentrations. The control data from the original screening load for the above specimen gives no indication of a reagent or instrument problem.

The reagent manufacturer has standardized their amphetamines kit with d-methamphetamine and supplies us with d-methamphetamine as the calibrator. Our high and low controls contain d-methamphetamine. Although the manufacturer claims to have equal response to d-amphetamine, there will always be some variability in the exact cross-reactivity. In order to monitor this more closely, we are including d-amphetamine in one of our batch controls.

This should prevent the re-occurrence of failing to detect d-amphetamine spiked samples. If you have any questions, call me at (770)452-1590.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Michael S. Feldman", with a long horizontal flourish extending to the right.

Michael S. Feldman, PhD  
Technical Manager, Substance Abuse Testing

cc: J. McHan, PhD